News
BRNS
0.9702
-29.70%
-0.4098
Barinthus Biotherapeutics Reports Promising IM-PROVE II Trial Results
TipRanks · 8h ago
Barinthus announces results from ongoing Phase 2b HBV003 trial
TipRanks · 8h ago
Arbutus and Barinthus announce new data from IM-PROVE II trial
TipRanks · 8h ago
Barinthus Bio Announces Results From Ongoing Phase 2b Chronic Hepatitis B Trial, Including Achievement of Functional Cure and HBsAb Seroconversion
Barchart · 14h ago
JMP Securities healthcare analysts hold an analyst/industry conference call
TipRanks · 4d ago
Weekly Report: what happened at BRNS last week (1104-1108)?
Weekly Report · 4d ago
Barinthus Biotherapeutics Price Target Maintained With a $5.00/Share by HC Wainwright & Co.
Dow Jones · 11/08 19:09
HC Wainwright & Co. Reiterates Buy on Barinthus Biotherapeutics, Maintains $5 Price Target
Benzinga · 11/08 18:59
Barinthus Biotherapeutics: Strong Financials and Promising Clinical Data Reinforce Buy Rating
TipRanks · 11/08 12:17
Barinthus Biotherapeutics GAAP EPS of -$0.21 beats by $0.24, revenue of $14.97M
Seeking Alpha · 11/06 15:56
Barinthus Biotherapeutics Q3 EPS $(0.21) Beats $(0.44) Estimate, Sales $14.97M
Benzinga · 11/06 13:18
Barinthus Biotherapeutics reports Q3 EPS (21c), consensus (44c)
TipRanks · 11/06 13:10
Weekly Report: what happened at BRNS last week (1028-1101)?
Weekly Report · 11/04 10:19
Weekly Report: what happened at BRNS last week (1021-1025)?
Weekly Report · 10/28 10:14
Weekly Report: what happened at BRNS last week (1014-1018)?
Weekly Report · 10/21 10:13
JMP Securities healthcare analysts hold an analyst/industry conference call
TipRanks · 10/16 18:05
Weekly Report: what happened at BRNS last week (1007-1011)?
Weekly Report · 10/14 10:28
Weekly Report: what happened at BRNS last week (0930-1004)?
Weekly Report · 10/07 10:22
Barinthus Biotherapeutics Price Target Maintained With a $5.00/Share by HC Wainwright & Co.
Dow Jones · 10/01 16:07
HC Wainwright & Co. Reiterates Buy on Barinthus Biotherapeutics, Maintains $5 Price Target
Benzinga · 10/01 15:56
More
Webull provides a variety of real-time BRNS stock news. You can receive the latest news about Barinthus Biotherapeutics plc through multiple platforms. This information may help you make smarter investment decisions.
About BRNS
Barinthus Biotherapeutics plc is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases and autoimmunity. Its pipeline, built around platform technologies; viral vector-based, consists of ChAdOx and MVA, and synthetic, consisting of SNAP-Tolerance Immunotherapy (SNAP-TI). These platforms help to develop antigen-specific immunotherapeutic candidates designed to optimize the disease fighting capabilities of T cells and guide them towards a healthy balance. It is focused on developing two key product candidates that harness its viral vector and synthetic platform technologies. These include VTP-300, a Phase II immunotherapeutic candidate designed as a potential component of a functional cure for chronic hepatitis B virus infection utilizing ChAdOx/MVA, and VTP-1000, its autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease.